Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Etrolizumab in Crohn's Disease
2014-003824-36Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Etrolizumab with Placebo (2 arms). Primary endpoint: Primary endpoint (Induction Phase). Started Jan 2015; status: completed.
02
Drugs
Etrolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-003824-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003824-36.